John P. Butler - 12 Dec 2018 Form 4/A - Amendment Insider Report for Akebia Therapeutics, Inc. (AKBA)

Role: CEO and President, Director
Signature: /s/ Nicole R. Hadas, attorney-in-fact for John P. Butler
Issuer symbol: AKBA
Transactions as of: 12 Dec 2018
Net transactions value: $0
Form type: 4/A - Amendment
Filing time: 18 Feb 2022, 20:55:44 UTC
Date Of Original Report: 13 Dec 2018
Next filing: 05 Aug 2021
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	AKBA	Common Stock	Other		+1,248	+0.33%		375,865	12 Dec 2018	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Pursuant to the Agreement and Plan of Merger, dated as of June 28, 2018 (as amended, the "Merger Agreement"), each share of common stock of Keryx Biopharmaceuticals, Inc. owned by the Reporting Person at the effective time of the transactions contemplated by the Merger Agreement was automatically converted into 0.37433 shares of the Issuer's common stock.
F2	The market value of each share of the Issuer's common stock received pursuant to the Merger Agreement is $8.94, based on the closing trading price of Akebia common stock on December 12, 2018.

Remarks:

This amendment on Form 4/A is being filed with the Securities and Exchange Commission to amend the Form 4, originally filed by the Reporting Person on December 13, 2018 (the "Original Form 4"), to report the transaction relating to 1,248 shares of common stock as set forth in Table I that was inadvertently omitted from Table I in the Original Form 4. This correction also effects (and is deemed to also correct and amend to the extent necessary) the total number of shares owned directly by Reporting Person following any transactions in any Form 4 filed subsequent to the Original Form 4.